At the news
? NEUTRALIMPACT 2/10 CLUSTER filed Jun 11, 2026 at 16:30 ET
Two Nuvalent insiders (CEO and Chief Development Officer) sold a combined ~$3.56M in open-market shares on June 8-9, 2026, alongside derivative exercises. The sales represent only ~0.04% of market cap and are routine option-exercise-related transactions. The dominant event is GSK's $10.6B acquisition of Nuvalent at $124/share, announced June 9, rendering these insider sales immaterial.
- CEO James Porter exercised 60,000 options (30k at $18.93, 30k at $0) and sold 12,495 shares for ~$1.10M on June 8.
- CDO Darlene Noci exercised 20,000 options (10k at $0, 10k at $1.08) and sold 20,000 shares for ~$2.46M on June 9.
- Total open-market sales: ~$3.56M, or 0.037% of Nuvalent's $9.7B market cap.
- GSK announced acquisition of Nuvalent for $124/share in cash on June 9, 2026, valuing equity at $10.6B.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access